Alexion Pharmaceuticals, Inc. ALXN announced a partnership with Complement Pharma to co-develop the preclinical C6 complement inhibitor, CP010, for neurodegenerative disorders. CP010 is a humanized ...

Alexion has announced a collaboration with Dicerna Pharmaceuticals to discover and develop RNA interference therapies for diseases caused by problems in the complement system. Boston-based Alexion ...

Alexion Pharmaceuticals and Complement Pharma will partner to develop a preclinical C6 complement inhibitor to treat neurodegenerative disorders. On June 11, 2018, Alexion Pharmaceuticals and ...

New Haven biotech Alexion Pharmaceuticals Inc. will partner with a startup in the Netherlands on a new drug to treat degenerative brain disorders. Alexion on Monday announced a deal with ...

Alexion has signed a deal with two Nordic biotechs to bolster its pipeline of potential rare disease drugs. The US pharma has announced partnerships with Denmark’s Zealand Pharma and Sweden’s Affibody ...

Alexion Pharmaceuticals, Inc has announced the submission of a biologics license application (BLA) to the US Food and Drug Administration (FDA) for approval of ALXN1210, the company’s investigational ...

Alexion is gearing up to file its experimental therapy for paroxysmal nocturnal hemoglobinuria (PNH) with regulators on both sides of the Altantic following the success of a late-stage clinical trial.

The transaction gives Alexion access to Achillion’s portfolio of oral small-molecule Factor D inhibitors to treat people with complement alternative pathway-mediated rare diseases. Alexion ...

For years, Alexion has been the only name in the game for a blood disease called paroxysmal nocturnal hemoglobinuria (PNH). Now, a number of Big Pharmas want in, vying to show their candidates can go ...